QQ客服 官方微博 反馈留言

浏览/检索结果: 共3条，第1-3条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsqu 期刊论文 2015, 卷号: 33, 期号: 15 作者:  Senan, Suresh;  Brade, Anthony M.;  Wang, Luhua;  Vansteenkiste, Johan F.;  Dakhil, Shaker R. 收藏  |  浏览/下载：7/0  |  提交时间：2020/01/04 Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsqu 会议论文 JOURNAL OF CLINICAL ONCOLOGY, 2015-05-20 作者:  Senan, Suresh;  Brade, Anthony M.;  Wang, Luhua;  Vansteenkiste, Johan F.;  Dakhil, Shaker R. 收藏  |  浏览/下载：7/0  |  提交时间：2020/01/13 PRELIMINARY SAFETY AND TREATMENT DELIVERY DATA DURING CONCURRENT PHASE OF CHEMORADIATION THERAPY OF THE PROCLAIM TRIAL: A PHASE 3 TRIAL OF PEMETREXED, CISPLATIN, AND RADIOTHERAPY FOLLOWED BY CONSOLIDATION PEMETREXED VERSUS ETOPOSIDE, CISPLATIN, A 期刊论文 2013, 卷号: 8, 页码: S551-S552 作者:  Vokes, Everett;  Wang, Luhua;  Vansteenkiste, Johan;  Dakhil, Shaker;  Biesma, Bonne 收藏  |  浏览/下载：1/0  |  提交时间：2020/01/13 pemetrexed  NSCLC  safety  PROCLAIM